+ A
A -
DPA
Islamabad
Phase 3 trials of a coronavirus vaccine developed by a Chinese company began in Pakistan on Tuesday, even as the country enjoys a sharp decline in new infections that has encouraged authorities to lift all virus-related restrictions. “Just launched the phase 3 trials of a Covid-19 vaccine in Pakistan,” Planning Minister Asad Umar announced in a tweet.
A total of 40,000 people - including 10,000 Pakistanis - will participate in this trial in seven countries, Umer said. The initial results are expected in four to six months, he added.
Trials of the vaccine candidate, developed by biopharmaceutical company CanSinoBio and the Beijing Institute of Biotechnology, are already under way in Argentina, Chile, China and Russia.
According to the National Institute of Health, which oversees the process, the first and second phase trials of the vaccine candidate, completed in May and June respectively, have shown promising results.
Several Chinese companies have joined in the global race to develop a vaccine to fight the coronavirus pandemic, which originated in China late last year.
Pakistan has witnessed a sharp decline in new coronavirus infections since July. That prompted the government to lift restrictions.
Earlier this month, it allowed schools to reopen.
The country has so far reported 306,866 coronavirus infections and 6,424 deaths. According to the Health Ministry, 582 new cases were reported during the last 24 hours, out of 36,155 tests.
Pakistan, China’s neighbour and long-time political ally, relies heavily on Beijing’s support for its troubled economy, which was struck hard by the pandemic.
Islamabad
Phase 3 trials of a coronavirus vaccine developed by a Chinese company began in Pakistan on Tuesday, even as the country enjoys a sharp decline in new infections that has encouraged authorities to lift all virus-related restrictions. “Just launched the phase 3 trials of a Covid-19 vaccine in Pakistan,” Planning Minister Asad Umar announced in a tweet.
A total of 40,000 people - including 10,000 Pakistanis - will participate in this trial in seven countries, Umer said. The initial results are expected in four to six months, he added.
Trials of the vaccine candidate, developed by biopharmaceutical company CanSinoBio and the Beijing Institute of Biotechnology, are already under way in Argentina, Chile, China and Russia.
According to the National Institute of Health, which oversees the process, the first and second phase trials of the vaccine candidate, completed in May and June respectively, have shown promising results.
Several Chinese companies have joined in the global race to develop a vaccine to fight the coronavirus pandemic, which originated in China late last year.
Pakistan has witnessed a sharp decline in new coronavirus infections since July. That prompted the government to lift restrictions.
Earlier this month, it allowed schools to reopen.
The country has so far reported 306,866 coronavirus infections and 6,424 deaths. According to the Health Ministry, 582 new cases were reported during the last 24 hours, out of 36,155 tests.
Pakistan, China’s neighbour and long-time political ally, relies heavily on Beijing’s support for its troubled economy, which was struck hard by the pandemic.
